Alnylam Pharmaceuticals, Inc. (ALNY)
328.16
-3.08
(-0.93%)
USD |
NASDAQ |
Feb 06, 16:00
325.00
-3.16
(-0.96%)
After-Hours: 20:00
Alnylam Pharmaceuticals EPS Diluted (Quarterly) : 1.840 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Insmed, Inc. | -1.747 |
| Biogen, Inc. | -0.3333 |
| Pfizer Inc. | -0.2898 |
| Eli Lilly & Co. | 7.390 |
| Bristol Myers Squibb Co. | 0.5326 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 251.08M |
| Revenue (Quarterly) | 1.249B |
| Total Expenses (Quarterly) | 997.94M |
| Enterprise Value | 43.40B |
| Gross Profit Margin (Quarterly) | 83.98% |
| Profit Margin (Quarterly) | 20.10% |
| Earnings Yield | 0.07% |
| Operating Earnings Yield | 0.61% |
| Normalized Earnings Yield | 0.4724 |